Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas-ko ikertzaileekin lankidetzan egindako argitalpenak (76)

2024

  1. A microRNA signature for valproate-induced steatosis in human hepatocytes and its application to predict fatty liver in paediatric epileptic patients on valproate therapy

    Toxicology, Vol. 509

  2. Assessing ATR-FTIR spectroscopy for steatosis quantification in liver biopsies in a long-duration cross-sectional study

    Microchemical Journal, Vol. 198

  3. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways

    International Journal of Molecular Sciences, Vol. 25, Núm. 10

  4. Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis

    International Journal of Molecular Sciences, Vol. 25, Núm. 5

  5. Progress and challenges of mid-infrared spectroscopy for liver characterization focusing on steatosis, fibrosis and cancer

    Applied Spectroscopy Reviews, Vol. 59, Núm. 4, pp. 578-599

  6. Uncovering the toxicity mechanisms of a series of carboxylic acids in liver cells through computational and experimental approaches

    Toxicology, Vol. 504

2023

  1. A robust reprogramming strategy for generating hepatocyte-like cells usable in pharmaco-toxicological studies

    Stem Cell Research and Therapy, Vol. 14, Núm. 1

  2. Comparing the direct assessment of steatosis in liver explants with mid- and near-infrared vibrational spectroscopy, prior to organ transplantation

    The Analyst, Vol. 148, Núm. 17, pp. 3986-3991

  3. Enhancing the accuracy of mid-infrared spectroscopy-based liver steatosis quantification using digital image analysis as a reference

    Analyst, Vol. 148, Núm. 13, pp. 3097-3106

  4. Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients

    Nutrients, Vol. 15, Núm. 14

  5. Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved

    Archives of Toxicology, Vol. 97, Núm. 6, pp. 1723-1738

  6. The assessment of the potential hepatotoxicity of new drugs by in vitro metabolomics

    Frontiers in Pharmacology, Vol. 14

2022

  1. A Novel UPLC-MS Metabolomic Analysis-Based Strategy to Monitor the Course and Extent of iPSC Differentiation to Hepatocytes

    Journal of Proteome Research, Vol. 21, Núm. 3, pp. 702-712

  2. Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen

    Antioxidants, Vol. 11, Núm. 5

  3. Modeling a Novel Variant of Glycogenosis IXa Using a Clonal Inducible Reprogramming System to Generate “Diseased” Hepatocytes for Accurate Diagnosis

    Journal of Personalized Medicine, Vol. 12, Núm. 7

  4. Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat

    International journal of molecular sciences, Vol. 23, Núm. 16

  5. The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment

    Metabolites, Vol. 12, Núm. 6

2021

  1. Extracting consistent biological information from functional results of metabolomic pathway analysis using the Mantel's test

    Analytica Chimica Acta, Vol. 1187

  2. Factors that influence the quality of metabolomics data in in vitro cell toxicity studies: a systematic survey

    Scientific Reports, Vol. 11, Núm. 1

  3. Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes

    Archives of Toxicology, Vol. 95, Núm. 9, pp. 3049-3062